It’s another digital chief for Big Pharma, this time at Sanofi. The French drugmaker tapped (PDF) chief medical officer Ameet Nathwani, M.D., as its first chief digital officer, combining the two roles inside the company just as it aims to join treatments and technology in the marketplace.
Nathwani will lead Sanofi’s efforts in merging research and development of new medicines with digital technology and big data, a Sanofi spokesperson said via email.
The combined role at Sanofi will focus on two main areas—developing a digital health strategy and capabilities, and using new technologies and advanced analytics to enhance or accelerate some of Sanofi’s core activities across the company, she said.
“The convergence of digital, analytics and science allows Sanofi to reinvent not just the way we work, but also what type of products we might offer in the future to patients around the world,” the spokesperson said. “We believe combining the CMO and CDO roles offers us a unique opportunity to leverage an understanding of life sciences, medicine and patient management combined with technology.”
Sanofi’s adoption of a chief digital officer follows other Big Pharma companies’ moves in the same direction, although it is unique in combining the role with chief medical officer. In 2018, Pfizer and Merck each named CDOs for the first time, following similar hires by Novartis and GlaxoSmithKline in 2017.
The shift comes as drugmakers realize that just developing medicines plus using technology isn’t enough in today’s healthcare market. They need to deliver digital lifestyle solutions. And to do that, they need big data and analytics integration.
Jamie Peck, managing director at Indegene’s new digital agency iON, talked to FiercePharma about the chief digital officer trend in December, and said, “When I started in this business, the person in charge of digital would be in the basement with the mainframes and the chief marketing officer was on the top floor with the cushy carpet. But now digital has moved to the top floor too. The digital and marketing heads now need to work hand-in-hand—and with the rest of the executive team.”
By Beth Snyder Bulik
Source: Fierce Pharma
As Novo Nordisk gears up to disrupt the obesity market with its newly approved weight-loss drug Wegovy, it is teaming with retail pharmacy giant CVS Health on a new education and nutrition coaching program for people taking anti-obesity meds.
The terms of the deal were undisclosed, but Atreca received $6 million from the Gates Foundation in 2012 to discover potential treatments for malaria, tuberculosis and HIV. The foundation has also given grant money to other biopharmas exploring malaria treatments, including Exscientia, which secured $4.2 million last year for such work.
At the start of the last decade, the IPO markets weren’t receptive to biotech companies. But by 2013, public investment was pouring into the industry, drawn by scientific advances and boosted by the newfound interest of a broader range of investors. Ever since, biotechs and their backers have ridden a multi-year boom. Keep track of them as they happen with this database.